Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€164.66

€164.66

0.650%
1.06
0.650%
€196.17
 
15:53 / Tradegate WKN: A1KBYX / Symbol: ZTS / Name: Zoetis / Stock / Pharmaceuticals / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Zoetis Inc. A Stock

The Zoetis Inc. A stock is trending slightly upwards today, with an increase of €1.06 (0.650%) compared to yesterday's price.
With 25 Buy predictions and 1 Sell predictions Zoetis Inc. A is one of the favorites of our community.
As a result the target price of 196 € shows a slightly positive potential of 19.03% compared to the current price of 164.66 € for Zoetis Inc. A.
Criterium "Business model" is seen as the biggest plus for Zoetis Inc. A stock. Negative votes have not been in the majority for any criteria for this stock

Pros and Cons of Zoetis Inc. A in the next few years

Pros
?
W********* I********* f** t** n*** y****
?
S********** s********
?
C******** o* t** e**********
Cons
?
B****
?
M***** P*******
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Zoetis Inc. A vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Zoetis Inc. A 0.650% 0.516% -1.529% 5.787% -7.987% -1.594% 62.269%
Pfizer Inc. 0.660% 1.637% 1.092% -19.420% 1.111% -20.858% -26.966%
Elanco Animal Health Inc. -0.240% -4.553% -25.802% 31.845% -6.967% -56.866% -
Biogen Inc. -2.250% 4.709% 3.663% -14.347% -7.591% -27.704% 6.840%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-12-04

When examining the financials of Zoetis (NYSE: ZTS), a leading company in the pharmaceutical industry, a preliminary review reveals a robust picture with consistent growth in total assets over the last three years. This growth is coupled with a stable increase in shareholder equity, indicating prudent financial management and a strong balance sheet foundation. A deeper dive into the detailed numbers should provide further insights into the organization's financial health, as well as potential areas of caution.

Growing Top Line: Zoetis has demonstrated a steady increase in total revenues, with the trailing twelve-month (TTM) revenue at approximately $8.37 billion. The year-over-year quarterly revenue growth of 7.4% signals a solid capacity for expanding their market presence and sales effectiveness.

EBITDA and Operating Margins: The EBITDA and operating margins are notable strengths, with a TTM EBITDA of around $3.47 billion and an operating margin of 37.1%. These numbers suggest efficient operational management and profitability.

Comments

Prediction Buy
Perf. (%) 7.92%
Target price 209.318
Change
Ends at 08.05.25

Zoetis Inc. (NYSE: ZTS) had its price target lowered by analysts at HSBC Holdings plc from $230.00 to $225.00. They now have a "buy" rating on the stock.
Ratings data for ZTS provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 6.92%
Target price 181.790
Change
Ends at 06.05.25

Zoetis Inc. (NYSE: ZTS) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $223.00 to $196.00. They now have a "buy" rating on the stock.
Ratings data for ZTS provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 9.12%
Target price 167.940
Change
Ends at 30.04.25

Zoetis Inc. (NYSE: ZTS) had its price target lowered by analysts at Stifel Nicolaus from $195.00 to $180.00. They now have a "buy" rating on the stock.
Ratings data for ZTS provided by MarketBeat
Show more

News

Beat the Dow Jones With This Cash-Gushing Dividend Stock: https://g.foolcdn.com/editorial/images/778424/animals-46.jpg
Beat the Dow Jones With This Cash-Gushing Dividend Stock

Since its spinoff from Pfizer in 2013, animal healthcare behemoth Zoetis (NYSE: ZTS) has seen its cash from operations nearly quintuple as a stand-alone company. Powered by a diverse array of animal

Zoetis (ZTS) Q1 2024 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg
Zoetis (ZTS) Q1 2024 Earnings Call Transcript

Image source: The Motley Fool.

Zoetis (NYSE: ZTS)Q1 2024 Earnings CallMay 02, 2024, 8:30 a.m. ET

Operator

Continue reading

Source Fool.com

Why Zoetis Stock Popped by Almost 6% on Thursday: https://g.foolcdn.com/editorial/images/775594/kitten-with-its-tongue-out-and-eyes-closed.jpg
Why Zoetis Stock Popped by Almost 6% on Thursday

Investors were meowing for animal healthcare specialist Zoetis (NYSE: ZTS) on Thursday, following the company's release of its latest quarterly results. These obviously pleased market participants